德展健康(000813) - 2021 Q1 - 季度财报

Financial Performance - The company's operating revenue for Q1 2021 was ¥211,589,350.75, a decrease of 55.01% compared to ¥470,318,621.70 in the same period last year[8]. - Net profit attributable to shareholders for Q1 2021 was ¥64,181,873.34, down 29.90% from ¥91,561,632.00 in the previous year[8]. - The net profit after deducting non-recurring gains and losses was ¥61,151,767.07, a decrease of 16.26% compared to ¥73,029,190.26 in the same period last year[8]. - Basic and diluted earnings per share for Q1 2021 were both ¥0.0287, a decrease of 30.51% from ¥0.0413 in the same period last year[8]. - Operating revenue decreased by 55.01% to ¥211.59 million, attributed to a decline in sales volume and selling price[20]. - Operating costs decreased by 48.21% to ¥64.15 million, mainly due to reduced sales volume[20]. - The company reported a significant increase in other payables, which rose to ¥361,794,769.19 from ¥295,209,596.61, a growth of approximately 22.5%[58]. - Total operating revenue for the current period is CNY 211,589,350.75, a significant decrease from CNY 470,318,621.70 in the previous period, representing a decline of approximately 55%[70]. - Net profit for the current period is CNY 57,996,391.95, compared to CNY 91,064,829.49 in the previous period, reflecting a decrease of approximately 36%[76]. - The total profit for the current period is CNY 70,774,219.94, compared to CNY 124,292,406.84 in the previous period, indicating a decline of about 43%[76]. Cash Flow - The net cash flow from operating activities was ¥154,051,928.33, down 66.20% from ¥455,715,435.22 in the previous year[8]. - Cash flow from operating activities was 154,051,928.33, significantly lower than 455,715,435.22 in the previous period, reflecting a decrease in cash generation[92]. - The company received cash of 410,866,105.80 from sales of goods and services, down from 679,122,808.80 in the previous period[88]. - Cash inflow from investment activities was 196,122,174.13, compared to 852,448,187.27 in the previous period, showing a substantial decline[92]. - Cash outflow from investment activities totaled 382,497,842.32, down from 1,800,786,324.78 in the previous period, indicating reduced investment spending[92]. - The ending cash and cash equivalents balance was 1,779,307,354.72, compared to 981,721,408.66 in the previous period, showing an increase in liquidity[94]. - The company paid 45,996,313.30 for goods and services, compared to 7,807,303.10 in the previous period, indicating increased operational costs[92]. - Cash inflow from investment activities totaled $238.10 million, a significant increase from $30.13 million in the previous period[98]. - Cash outflow from investment activities was $308.42 million, compared to $827.55 million last year, resulting in a net cash flow from investment activities of -$70.31 million[98]. - The net increase in cash and cash equivalents was -$57.80 million, compared to -$783.68 million in the previous period[98]. Assets and Liabilities - Total assets at the end of the reporting period were ¥6,466,510,166.45, an increase of 1.05% from ¥6,399,443,473.17 at the end of the previous year[8]. - Current liabilities rose to ¥422,914,640.32 from ¥413,027,453.20, representing an increase of approximately 2.14%[58]. - Total liabilities amounted to ¥455,413,057.28, compared to ¥446,366,740.11, showing a growth of around 2.34%[58]. - The company's total liabilities amount to CNY 1,900,781,079.04, slightly up from CNY 1,839,629,493.35 in the previous period, showing an increase of about 3%[68]. - Total equity stands at CNY 11,004,429,346.89, a minor decrease from CNY 11,023,162,063.91 in the previous period, representing a decline of approximately 0.17%[68]. Investments and R&D - The company increased its investment in Beijing Dongfang Lue Bio-pharmaceutical Technology Co., Ltd., raising its stake to 23.22%[23]. - The company announced positive results from a Phase III clinical trial for a DNA therapeutic drug in collaboration with Inovio Pharmaceuticals[23]. - The R&D project for cardiovascular and tumor treatment drugs is facing increased difficulty due to changes in national drug review policies[35]. - Research and development expenses for the current period are CNY 18,800,084.65, an increase from CNY 15,569,693.37 in the previous period, indicating a growth of about 20%[73]. Shareholder Information - The top shareholder, Meilin Holdings Group, holds 24.44% of the shares, with a total of 547,744,307 shares[13]. - The total number of ordinary shareholders at the end of the reporting period was 49,903[13]. Miscellaneous - The company has not engaged in derivative investments during the reporting period[28]. - The company has not reported any overdue commitments from actual controllers, shareholders, or related parties during the reporting period[26]. - The company has not engaged in any research, communication, or interview activities during the reporting period[48]. - The company has not reported any significant contracts or non-operating fund occupation by controlling shareholders during the reporting period[46][47].